According to the research report titled ‘GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027’, available with Market Study Report, global Alzheimer’s disease therapeutics and diagnostic market is anticipated to grow with a CAGR of 7.78%, while accumulating massive revenues over 2019-2027.
 

The report cites that worldwide Alzheimer’s disease therapeutics & diagnostics market is majorly driven by surging cases of Alzheimer’s disease across globe. Other factors including improved affordability of therapeutics and increasing demand for personalized drugs will augment the market outlook in the coming years.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2515930/
 

Governments across the globe are allocating funds for research & development activities, which along with demographic shift towards geriatric population who are more prone to acquiring to Alzheimer’s disease will boost the demand for Alzheimer’s disease therapeutics and diagnostics solutions. Also, emergence of in-vitro diagnostics and inflowing investments for development of personalized drugs will create lucrative growth opportunities for the market partakers.
 

On the contrary, costly therapies available for treatment of Alzheimer’s ailment, alongside dearth of skilled medical professionals in developing nations are posing challenges for global Alzheimer’s disease therapeutics and diagnostics industry trends. Moreover, strict standards for clinical trials & development of new drugs in consort with limited cognizance regarding disease therapeutics will hinder the market growth over 2019-2027.
 

As per the report, different diagnostic types prevailing in global Alzheimer’s disease therapeutics and diagnostics industry are computed tomography, magnetic resonance imaging, electroencephalography, positron emission tomography, and lumbar puncture test.
 

From the regional perspective, Asia Pacific currently holds a strong presence in worldwide Alzheimer’s disease therapeutics and diagnostics market, which is also reckoned to grow at rapid pace over 2019-2027. The positive market trends are credited to massive federal investments towards R&D activities for personalized drugs and diagnostic tests. Presence of baby boomer population in the region with higher susceptibility to this disorder will further sway business dynamics in Asia Pacific.
 

Key players profiled in global Alzheimer’s disease therapeutics and diagnostics industry report are Sun Pharmaceutical Industries Ltd., Siemens Healthineers AG, Piramal Enterprises Ltd., Johnson & Johnson, Merck & Co., GE Healthcare, Roche Holding AG, DiaGenic ASA, COGNOPTIX, Biogen Inc., Baxter International Inc., Axon Neuroscience SE, Amarantus BioScience Holdings Inc., and AbbVie Inc.